

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 May 2011 (05.05.2011)

PCT

(10) International Publication Number
WO 2011/053743 A1

(51) International Patent Classification:
G01N 33/53 (2006.01)

(21) International Application Number:
PCT/US2010/054595

(22) International Filing Date:
29 October 2010 (29.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/256,752 30 October 2009 (30.10.2009) US
61/368,081 27 July 2010 (27.07.2010) US

(71) Applicant (for all designated States except US): **MERCK SHARP & DOHME CORP.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): **ICHETOVKIN, Marina** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **CHEN, Zhu** [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LEGRAND, Cheryl** [US/US]; 776 Crestmont Lane, Langhorne, PA 19047 (US).

(74) Common Representative: **MERCK SHARP & DOHME CORP.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

[Continued on next page]

(54) Title: PCSK9 IMMUNOASSAY




FIG. 1A




FIG. 1B

(57) Abstract: Methods of using PCSK9 antagonists. More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay.

WO 2011/053743 A1

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

TITLE OF THE INVENTION

PCSK9 IMMUNOASSAY

BACKGROUND OF THE INVENTION

5 Proprotein convertase subtilisin-kexin type 9 (PCSK9), also known as neural apoptosis- regulated convertase 1 (NARC-1), is a proteinase K-like subtilase identified as the 9th member of the secretory subtilase family (Seidah, N.G., *et al.*, 2003 PROC NATL ACAD SCI USA 100:928-933). PCSK9 is expressed in cells capable of proliferation and differentiation such as hepatocytes, kidney mesenchymal cells, intestinal ileum, colon epithelia and embryonic brain
10 telencephalic neurons (Seidah *et al.*, 2003).

 The gene for human PCSK9 has been sequenced and found to be about 22-kb long with 12 exons that encode a 692 amino acid protein (NP_777596.2). PCSK9 is disclosed and/or claimed in several patent publications, including: PCT Publication Nos. WO 01/31007, WO 01/57081, WO 02/14358, WO 01/98468, WO 02/102993, WO 02/102994, WO 02/46383, WO
15 02/90526, WO 01/77137, and WO 01/34768; US Publication Nos. US 2004/0009553 and US 2003/0119038, and European Publication Nos. EP 1 440 981, EP 1 067 182, and EP 1 471 152.

 PCSK9 has been implicated in cholesterol homeostasis, as it appears to have a specific role in cholesterol biosynthesis or uptake. In a study of cholesterol-fed rats, Maxwell *et al.* found that PCSK9 was downregulated in a similar manner to other genes involved in
20 cholesterol biosynthesis, (Maxwell *et al.*, 2003 J. LIPID RES. 44:2109-2119). The expression of PCSK9 was regulated by sterol regulatory element-binding proteins (SREBP), which is seen in other genes involved in cholesterol metabolism (Maxwell, *et al.*, 2003).

 Additionally, PCSK9 expression is upregulated by statins in a manner attributed to the cholesterol-lowering effects of the drugs (Dubuc *et al.*, 2004 ARTERIOSCLER. THROMB. VASC. BIOL. 24:1454-1459). Adenoviral expression of PCSK9 has been shown to lead to a notable time-dependent increase in circulating low density lipoprotein (LDL) (Benjannet *et al.*, 2004 J. BIOL. CHEM. 279:48865-48875) and mice with PCSK9 gene deletions have increased levels of hepatic LDL receptors (LDLR) and clear LDL from the plasma more rapidly (Rashid *et al.*, 2005 PROC. NATL. ACAD. SCI. USA 102:5374-5379). Medium from HepG2 cells transiently
30 transfected with PCSK9 reduce the amount of cell surface LDLRs and internalization of LDL when transferred to untransfected HepG2 cells (Cameron *et al.*, 2006 HUMAN MOL. GENET. 15:1551-1558). It has been further demonstrated that purified PCSK9 added to the medium of

HepG2 cells had the effect of reducing the number of cell-surface LDLRs in a dose- and time-dependent manner (Lagace *et al.*, 2006 J. CLIN. INVEST. 116:2995-3005).

A number of mutations in the gene PCSK9 have also been conclusively associated with autosomal dominant hypercholesterolemia (ADH), an inherited metabolism disorder characterized by marked elevations of low density lipoprotein (“LDL”) particles in the plasma which can lead to premature cardiovascular failure (e.g., Abifadel *et al.*, 2003 NATURE GENETICS 34:154-156; Timms *et al.*, 2004 HUM. GENET. 114:349-353; Leren, 2004 CLIN. GENET. 65:419-422).

It therefore appears that PCSK9 plays a role in the regulation of LDL production. Expression or upregulation of PCSK9 is associated with increased plasma levels of LDL cholesterol, and inhibition or the lack of expression of PCSK9 is associated with low LDL cholesterol plasma levels. Significantly, lower levels of LDL cholesterol associated with sequence variations in PCSK9 confer protection against coronary heart disease (Cohen, *et al.*, 2006 N. ENGL. J. MED. 354:1264-1272).

Clinical trial data have demonstrated that reductions in LDL cholesterol levels are related to the rate of coronary events (Law *et al.*, 2003 BMJ 326:1423-1427). Moderate lifelong reduction in plasma LDL cholesterol levels has been shown to be substantially correlated with a substantial reduction in the incidence of coronary events (Cohen *et al.*, 2006, *supra*), even in populations with a high prevalence of non-lipid-related cardiovascular risk factors. Accordingly, there is great benefit to be reaped from the managed control of LDL cholesterol levels.

Accordingly, it would be desirable to further investigate PCSK9 as a target for the treatment of cardiovascular disease. Antibodies useful as PCSK9 antagonists have been identified and have utility as therapeutic agents. In support of such investigations, it would be useful to have a method for measuring levels of circulating PCSK9 in a biological sample which has been exposed to a PCSK9 antagonist, such as an antibody.

It would be further desirable to be able to identify novel PCSK9 antagonists in order to assist in the quest for compounds and/or agents effective in the treatment of cardiovascular disease. Hence, a method for measuring levels of circulating PCSK9 in a biological sample for such purposes as, e.g., assessing the effectiveness of a putative PCSK9 antagonist is desirable.

Additionally, it would be of use to provide kits to assay levels of circulating PCSK9 in biological samples.

SUMMARY OF THE INVENTION

The present invention relates to a method of measuring circulating PCSK9 levels in a biological sample. Said method comprises the steps of performing an immunoassay on a biological sample obtained from a subject and comparing the level of PCSK9 in said sample against a standard
5 having a known concentration of PCSK9.

The present invention further relates to a method for identifying novel PCSK9 antagonists, comprising the steps of performing an immunoassay on a biological sample which has been contacted with a putative PCSK9 antagonist and comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9.

10 A further aspect of the present invention relates to a kit for measuring circulating PCSK9 levels in a biological sample, wherein said kit comprises:

a). a biological sample collection device;

b). a composition comprising an immunoassay which comprises a coating or capture antibody and a detection antibody;

15 and c). a means for detecting a reaction between PCSK9 antigen in the sample and antibodies in the immunoassay.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURES 1A-B illustrates the Lanthanide Chelate Delay time and Stokes' shift.

20 FIGURE 2 illustrates the recombinant human PCSK9 standard curve diluted in assay buffer. The range of the curve is 10.26 nM to 0.005 nM.

FIGURE 3 illustrates the biological variability of six normal healthy volunteers shown on three different days over three weeks. Concentration shown in nM.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of measuring circulating PCSK9 levels in a biological sample, comprising the steps of performing an immunoassay on a biological sample obtained from a subject and comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9. The present assay is of particular utility for
30 measuring human PCSK9.

An immunoassay is an analysis or methodology that utilizes an antibody to specifically bind an analyte. The immunoassay is characterized by the use of specific binding properties of at least one particular antibody to isolate, target or quantify the analyte.

In particular embodiments, the immunoassay comprises the steps of: (a) depositing a biological sample on a support having immobilized bound anti-PCSK9 antibody AX213 bound thereto; (b) contacting the support having the biological sample deposited thereon with anti-PCSK9 antibody AX1 bearing a detectable label; and (c) detecting the label.

5 PCSK9 refers to proprotein convertase subtilisin-kexin type 9 (PCSK9), also known as neural apoptosis- regulated convertase 1 (NARC-1), a proteinase K-like subtilase identified as the 9th member of the secretory subtilase family (Seidah, N.G., *et al.*, 2003 PROC NATL ACAD SCI USA 100:928-933), as defined in the literature and, unless otherwise stated, includes both the soluble and insoluble forms. The term may in appropriate context refer to
10 either an antigenic component thereof or the genetic locus.

AX213 is an antibody molecule comprising a variable light ("VL") sequence comprising SEQ ID NO: 3 and a variable heavy ("VH") sequence comprising SEQ ID NO: 7. In particular embodiments, AX213 is a full length antibody molecule. In specific embodiments, AX213 is an IgG antibody molecule, and in particular embodiments, an IgG2. In specific
15 embodiments, AX213 comprises (a) light chain comprising SEQ ID NO: 1 or SEQ ID NO: 11 and (b) a heavy chain comprising SEQ ID NO: 9.

AX1 is an antibody molecule comprising a variable light ("VL") sequence comprising SEQ ID NO: 15 and a variable heavy ("VH") sequence comprising SEQ ID NO: 19. In particular embodiments, AX1 is a full length antibody molecule. In specific embodiments,
20 AX213 is an IgG antibody molecule, and in particular embodiments, an IgG2. In specific embodiments, AX213 comprises (a) light chain comprising SEQ ID NO: 13 or SEQ ID NO: 23 and (b) a heavy chain comprising SEQ ID NO: 21.

Antibody molecules can exist, for example, as intact immunoglobulins or as a number of well characterized fragments produced by, for example, digestion with various
25 peptidases. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as a myriad of immunoglobulin variable region genes. Light chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. "Whole" antibodies or "full length" antibodies often refers to proteins that comprise two heavy (H) and
30 two light (L) chains inter-connected by disulfide bonds which comprise: (1) in terms of the heavy chains, a variable region (abbreviated herein as "V_H") and a heavy chain constant region which comprises three domains, C_{H1}, C_{H2}, and C_{H3}; and (2) in terms of the light chains, a light chain variable region (abbreviated herein as "V_L") and a light chain constant region which comprises

one domain, C_L. Pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)₂, a dimer of Fab which itself is a light chain joined to V_H-C_{H1} by a disulfide bond. The F(ab)₂ may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the F(ab)₂ dimer into an Fab' monomer. The Fab' monomer is essentially a Fab with part of the hinge region broken. While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies.

In specific embodiments, the AX213 and AX1 antibody molecules are, independently, isolated prior to use. "Isolated", as used herein, refers to a property that makes them different from that found in nature. The difference can be, for example, that they are of a different purity than that found in nature, or that they are of a different structure or form part of a different structure than that found in nature. A structure not found in nature, for example, includes recombinant human immunoglobulin structures. Other examples of structures not found in nature are antibody molecules substantially free of other cellular material.

A detectable label, as used herein, refers to another molecule or agent incorporated into or affixed to the antibody molecule. In one embodiment, the label is a detectable marker, *e.g.*, a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (*e.g.*, streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (*e.g.*, ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I), fluorescent labels (*e.g.*, FITC, rhodamine, lanthanide phosphors), enzymatic labels (*e.g.*, horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (*e.g.*, leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), magnetic agents, such as gadolinium chelates, toxins such as pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine,

lidocaine, propranolol, and puromycin, and analogs or homologs thereof. In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

In particular embodiments of the present invention, the immunoassay is a solid phase immunoassay. In specific embodiments, the solid phase immunoassay is a dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA). However, it is within the scope of the current invention to use any solution-based or solid phase immunoassay as will be well familiar to those of skill in the art. Such assays include, without limitation, assays using magnetic beads as labels in lieu of enzymes, ELISAs, radioisotopes, or fluorescent moieties (fluorescent immunoassays).

The biological sample is selected from the group consisting of blood, plasma and serum. In particular embodiments, the blood, plasma and serum are derived from a mammalian subject including but not limited to humans.

The present invention further relates to a method for measuring PCSK9 in the presence of a putative PCSK9 antagonist. Said method comprises the steps of performing an immunoassay on a biological sample which has been contacted with a putative PCSK9 antagonist and comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9. In particular embodiments, the method comprises (a) depositing the biological sample on a support having immobilized anti-PCSK9 antibody AX213; (b) contacting the support having the biological sample deposited thereon with anti-PCSK9 antibody AX1 bearing a detectable label; (c) detecting the label; and (d) comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9. In a preferred embodiment, the immunoassay is a solid phase immunoassay. In a more preferred embodiment, the solid phase immunoassay is a dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA).

The anti-PCSK9 immobilized antibody AX213, in specific embodiments, is coated on plates (in particular embodiments, black high binding assay plates) overnight. In particular embodiments, black high binding assay plates are coated overnight at 4°C with 100-500ng/well of AX213 antibody.

The biological sample is selected from the group consisting of blood, plasma and serum. In particular embodiments, the blood, plasma and serum are derived from a mammalian subject including but not limited to humans.

In particular embodiments, 10-50 ng/well of biotinylated AX1IgG is used for antigen detection.

Use of the term "antagonist" or derivatives thereof (*e.g.*, "antagonizing") refers to the fact that the subject molecule or agent can antagonize, oppose, counteract, inhibit, neutralize,

or curtail the functioning of PCSK9. In specific embodiments, the antagonist reduces the functioning or activity of PCSK9 by at least 10%, or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. Reference herein to PCSK9 function or PCSK9 activity refers to any function or activity that is driven by, requires, or is exacerbated or enhanced by PCSK9.

5 The present invention additionally relates to a kit for measuring circulating PCSK9 levels in a biological sample, comprising:

- a). a biological sample collection device;
- b). a composition comprising an immunoassay which comprises a coating or capture antibody and a detection antibody;

10 and c). a means for detecting a reaction between PCSK9 antigen in the sample and antibodies in the immunoassay; wherein the coating or capture antibody is AX213 and the detecting antibody is AX1.

In particular embodiments, the kit comprises the AX213 antibody immobilized on a support.

15 Kits typically but need not include a label indicating the intended use of the contents of the kit. The term label in the context of the kit includes any writing, or recorded material supplied on or with the kit, or which otherwise accompanies the kit.

The examples below are provided to illustrate the present invention without limiting the same hereto. The following list of acronyms are employed therein:

- 20 BSA: bovine serum albumin
- ddH2O double distilled water
- EDTA: Ethylenediaminetetraacetic Acid
- IPTG: Isopropyl-Beta-d-Thiogalactopyranoside
- PBS: Phosphate-buffered saline
- 25 PBST or PBS-T: Phosphate-buffered saline containing Tween
- TBS-T: Tris-buffered saline containing Tween

EXAMPLE 1

PCSK9 Antagonists AX213 & AX1

30 The PCSK9 antagonists used in this assay are antibodies AX213 and AX1. AX213 and AX1 are disclosed in copending applications serial nos. 61/256,732 and 61/256,720 filed October 30, 2009, which are incorporated in their entirety herein.

PDL1 Phage Library Panning Against PCSK9 Protein: AX1 and AX213 were identified by panning the VH3/Vκ3 and VH3/Vκ1 PDL1 Abmaxis synthetic human Fab libraries

against human PCSK9. Antigen protein PCSK9 was coated on Maxisorp well stripe (Nunc-Immuno Modules) at a concentration of 1-10 µg/ml for overnight at 4 °C. Multiple wells of antigen were prepared for each library. 5% milk in PBS was used to block the coated wells at room temperature for 1-2 hours. After a wash with PBS, 100 µl of phage library solution/well (usually 1-5 x10¹² in 2% milk-PBS) was added into 4 parallel wells, and incubated for designed length of time (usually 1-2 hours). After several washings with PBST and PBS, the bound phages were eluted from the wells with fresh-prepared 1.4% triethylamine in ddH₂O (10 minutes incubation at room temperature), followed immediately with neutralization by adding 50 µl of 1M Tris-HCl (pH 6.8).

The eluted, enriched phage pool was further amplified through the following steps: First, TG1 cells were infected with eluted phages at 37 °C for 1 hour, then plated out on 2YT agar plates with 2% glucose and 100 µg/ml carbenicillin for overnight culture. Thus TG1 cells harboring enriched phagemid library were harvested from the plates, and infected with helper phage GMCT for 1 hour. The Fab-display phages were then generated from those TG1 cells harboring both library phagemids and GMCT helper phage genome by overnight growth in 2xYT/ carbenicillin /Kanamycin at 22 °C. The phagemid particles were purified from overnight culture supernatants by precipitation with PEG/NaCl, and re-suspended in PBS. The PEG-precipitation was repeated once. The phage concentration was determined by OD₂₆₈ measurement.

With amplified first round phages, the panning process as described above was repeated twice for further enrichment of PCSK9-binding phages. The eluted phages from the third round panning were used to infect TG1 cells. The TG1 cells harboring phagemids from third round panning were picked from 2YT agar plates for Fab ELISA screening assay.

Fab ELISA Screening For PCSK9 Binders: Over 10,000 clones from third round panning were picked by MegaPix Picking Robot (Genetix), and inoculated into 384-well plates with 60 µl of 2YT/2% Glucose/ carbenicillin for overnight culture at 30 °C with 450 rpm shaking. The duplicated plates were made by transferring ~1-3 µl overnight culture from each well into new plates with 50µl/well of 2YT/0.1% Glucose/carbenicillin. The duplicated plates were incubated in a shaker at 30 °C for 6 hours, then 10 µl/well of IPTG was added for a final concentration of 1mM. After overnight culture at 22 °C , the soluble Fab in IPTG-induction plates were released by adding lysozyme into each well.

To detect the antigen binding activity of soluble Fabs generated from the above experiment, the antigen plates were generated by overnight coating of 5 µg/ml antigen. After blocking with milk-PBS and a wash with PBST, 15-20 µl of Fab samples from IPTG-induction plates was transferred into antigen plates for 1-2 hours incubation at room temperature. The plates were washed 5 times with PBS-T, and added with 1:2000 diluted goat anti-human Kappa-HRP (SouthernBiotech Cat. No. 2060-05) or 1:10,000 diluted goat anti-human Fab-HRP in 5% MPBS for 1 hour incubation. After washing away unbound HRP-conjugates with PBST, the substrate solution QuantaBlu WS (Pierce 15169) was then added to each well and incubated for 5-15 minutes. The relative fluorescence units (RFU) of each well was measured to determine the Fab binding activity by using excitation wavelength 330nm and emission detection wavelength 410nm.

The ELISA results showed 30 to 80% clones from third round panning of individual PDL1 sun-libraries bound to antigen PCSK9. The positive clones were then sent out for DNA sequencing.

The sequences are set forth as follows:

AX213

AX213 FULL LIGHT CHAIN PROTEIN [SEQ ID NO: 1]

EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQKPGQAPRLLIYDASNRATGIPAR
 FSGSGSGTDFLTLSISLEPEDFAVYYCQVWDSPPVVFSGGKVEIKRTVAAPSVFIFPPSD
 20 EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
 SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

AX213 FULL LIGHT CHAIN NUCLEIC ACID [SEQ ID NO: 2]

GAAATCGTGCTGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCCGGGGAACGTGCC
 ACCATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGAACTGGTATCAGCAG
 25 AAGCCAGGTCAGGCGCCACGTCTGCTGATCTACGACGCCTCTAACCGTGCCACCGGT
 ATCCCAGCCCGTTTCTCTGGTTCTGGTTCTGGCACCGACTTCACCCTGACCATCTCTT
 CTCTGGAACCAGAAGACTTCGCCGTGTACTACTGCCAGGTATGGGACAGCTCTCCTC
 CTGTGGTGTTCGGTGGTGGTACCAAAGTGGAAATCAAGCGTACGGTGGCTGCACCAT
 CTGTATTCATCTTCCC GCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGT
 30 GTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATA
 ACGCCCTCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAGGAC
 AGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGAAACA

CAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGA
GCTTCAACAGGGGAGAGTGT

AX213-VL [SEQ ID NO: 3], CDRs underlined

EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASNRATGIPAR
5 FSGSGSGTDFTLTISSLEPEDFAVYYCQVWDSSPPVVFVGGGKVEIK

AX213-VL [SEQ ID NO: 4]

GAAATCGTGCTGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCCGGGGAACGTGCC
ACCATCACCTGCCGTGCCTCTCAGTATGTCGGCAGCTACCTGAACTGGTATCAGCAG
AAGCCAGGTCAGGCGCCACGTCTGCTGATCTACGACGCCTCTAACCGTGCCACCGGT
10 ATCCCAGCCCGTTTCTCTGGTTCTGGTTCTGGCACCGACTTCACCCTGACCATCTCTT
CTCTGGAACCAGAAGACTTCGCCGTGTACTACTGCCAGGTATGGGACAGCTCTCCTC
CTGTGGTGTTCGGTGGTGGTACCAAAGTGGAGATCAA

AX213 FD CHAIN (FOR FABS) PROTEIN [SEQ ID NO: 5]

QVQLLESGLLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTR
15 YNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARANDGYSFDYWGQGLVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKEPKSCDKTHT

AX213 FD CHAIN (FOR FABS) NUCLEIC ACID [SEQ ID NO: 6]

caggtgcaattgctggaatctggtgggtctggtgcagccaggtggttctctgcgtctgtctgcaaggctagcgggtacaccttctctcgcta
20 cggtatcaactgggtgcgtcagccaccaggtggaagggtctggaatggatcggctggatcagccaggtaacgggtggtactaggtacaacgaa
aagtcaagggtgtaaggccacctctctagagacaactctaagaacacctgtacttgcagatgaactctctgcgtgccgaggacactgcagtg
tactactgcgcccgtgcaaatgacgggtactcctcgactactggggtcaggttacgctggtgactgtctcgagcgaagcaccacaaaggccc
atcgggtattccccctggcaccctcctcaagagcacctctgggggcacagcggccctgggctgctggtcaaggactactccccgagccg
gtgacgggtgctggaactcagcgcctctgaccagcggcgtgcacacctccccggctgtcctacagtcctcaggactctactccctcagcag
25 cgtggtgactgtgccctccagcagctgggcacccagacctacatctgcaacgtgaatcacaagcccagcaaacactaaggtggacaagaaa
gttgagcccaaatctgtgacaaaactcacaca

AX213-VH [SEQ ID NO: 7], CDRs underlined

EVQLLESGLLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTR
YNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARANDGYSFDYWGQGLVTV

30 SS

AX213-VH [SEQ ID NO: 8]

CAGGTGCAATTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGT
 CTGTCTTGCAAGGCTAGCGGTTACACCTTCTCTCGCTACGGTATCAACTGGGTGCGT
 CAGGCACCAGGTAAGGGTCTGGAATGGATCGGTCGGATCGACCCAGGTAACGGTGG
 5 TACTAGGTACAACGAAAAGTTCAAGGGTAAGGCCACCATCTCTAGAGACAACTCTA
 AGAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACT
 ACTGCGCCCGTGCAAATGACGGTACTCCTTCGACTACTGGGGTCAGGGTACGCTGG
 TGA CTGTCTCGAGC

AX213 IGG2 HEAVY CHAIN PROTEIN [SEQ ID NO: 9]

10 EVQLLESGGGLVQPGGSLRLSCKASGYTFSRYGINWVRQAPGKGLEWIGRIDPGNGGTR
 YNEKFKGKATISRDNSKNTLYLQMNSLRAEDTAVYYCARANDGYSFDYWGQGLVTV
 SSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSVHTFPAVLQ
 SSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPAPPVAGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNS
 15 TFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREE
 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSGSSFLYSKLTVDKSR
 WQQGNVFSVCSVMHEALHNHYTQKSLSLSPGK

AX213 IGG2 HEAVY CHAIN NUCLEIC ACID [SEQ ID NO: 10]

GAGGTCCAACCTTTGGAGTCTGGAGGAGGACTGGTCCAACCTGGAGGCTCCCTGAG
 20 ACTGTCCTGTAAGGCATCTGGCTACACCTTCAGCAGATATGGCATCAACTGGGTGAG
 ACAGGCTCCTGGCAAGGGATTGGAGTGGATTGGCAGGATTGACCCTGGCAATGGAG
 GCACCAGATAACAATGAGAAGTTCAAGGGCAAGGCTACCATCAGCAGGGACAACAGC
 AAGAACACCCTCTACCTCCAAATGAACTCCCTGAGGGCTGAGGACACAGCAGTCTA
 CTACTGTGCCAGGGCTAATGATGGCTACTCCTTTGACTACTGGGGACAAGGCACCCT
 25 GGTGACAGTGTCTCTGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTG
 CTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACT
 TCCCCGAACCGGTGACGGTGTCTGTTGAACTCAGGCGCTCTGACCAGCGGCGTGCAC
 ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACC
 GTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTTAGATCACAAGCCC
 30 AGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTGCGAGTGCCACC
 GTGCCCAGCACCACTGTGGCAGGACCGTCAGTCTTCCCTCTTCCCCCAAACCCAA
 GGACACCCTCATGATCTCCCGGACCCCTGAGGTACCGTGCCTGGTGGTGGACGTGAG
 CCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA

ATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGC
 GTCTCACCCTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT
 CTCCAACAAAGGCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAACCAAGGGC
 AGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAG
 5 AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTG
 GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACACCTCCCATGCT
 GGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTG
 GCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTA
 CACACAGAAGAGCCTCTCCCTGTCTCCGGGTAAA

10 **AX213 FULL LIGHT CHAIN PROTEIN [SEQ ID NO: 11]**

EIVLTQSPATLSLSPGERATITCRASQYVGSYLNWYQQKPGQAPRLLIYDASN RATGIPAR
 FSGSGSGTDFTLTISLPEPDAFVYYCQVWDSPPVVFGGGKVEIKRTVAAPSVFIFPPSD
 EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTL
 SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

15 **AX213 IGG LIGHT CHAIN PAIRED WITH IGG2 NUCLEIC ACID [SEQ ID NO: 12]**

GAGATTGTGCTGACCCAGAGCCCTGCCACCCTGTCCCTGAGCCCTGGAGAGAGGGC
 TACCATCACTTGTAGGGCAAGCCAATATGTGGGCTCCTACCTGAACTGGTATCAACA
 GAAGCCTGGACAAGCCCCAAGACTGCTGATTTATGATGCCAGCAACAGGGCTACAG
 GCATCCCTGCCAGGTTCTCTGGCTCTGGCTCTGGCACAGACTTCACCCTGACCATCTC
 20 CTCCTTGGAACCTGAGGACTTTGCTGTCTACTACTGTCAGGTGTGGGACTCCAGCCC
 TCCTGTGGTGTGGAGGAGGCACCAAGGTGGAGATTAAGCGTACGGTGGCTGCAC
 CATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGT
 TGTGTGCTGCTGAATAACTTCTATCCAGAGAGGCCAAAGTACAGTGGAAGGTGG
 ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACAGAGCAGGACAGCAAG
 25 GACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAA
 ACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAA
 AGAGCTTCAACAGGGGAGAGTGT

AX1

AX1 FULL LIGHT CHAIN PROTEIN [SEQ ID NO: 13]

30 DIQMTQSPSSLSASVGDRTITCRASQDISRYLAWYQQKPGKAPKLLIYAASSLQSGVPS
 RFSGSGSGTDFTLTISLQPEDFATYYCAAYDYSLGGYVFGDGTKVEIKRTVAAPSVFIFP
 PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSST
 LTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

AX1 FULL LIGHT CHAIN NUCLEIC ACID [SEQ ID NO: 14]

GACATCCAGATGACCCAGTCTCCATCTTCTCTGTCTGCCTCTGTGGGCGACCGGGTG
 ACCATCACCTGCCGTGCCTCTCAGGATATCTCTAGGTATCTGGCCTGGTATCAGCAG
 AAGCCAGGTAAGGCGCCAAAGCTGCTGATCTACGCCGCCTCTTCTTTGCAGTCTGGT
 5 GTGCCATCTCGTTTCTCTGGTTCTGGTTCTGGCACCGACTTCACCCTGACCATCTCTT
 CTTTGCAGCCAGAAGACTTCGCCACCTACTACTGCGCGGCTTACGACTATTCTTTGG
 GCGGTTACGTGTTTCGGTGATGGTACCAAAGTGGAGATCAAACGTACGGTGGCTGCA
 CCATCTGTCTTCATCTTCCC GCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTG
 TTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG
 10 ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTACACAGAGCAGGACAGCAAG
 GACAGCACCTACAGCCTCAGCAGCACCTGACGCTGAGCAAAGCAGACTACGAGAA
 ACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAA
 AGAGCTTCAACAGGGGAGAGTGT

AX1-VL [SEQ ID NO: 15], CDRs underlined

15 DIQMTQSPSSLSASVGDRVTITCRASQDISRYLA WYQQKPGKAPKLLIYAAASSLQSGVPS
 RFSGSGSGTDFTLTISSLQPEDFATYYCAAYDYSLGYYVFGDGTKVEIK

AX1-VL [SEQ ID NO: 16]

GACATCCAGATGACCCAGTCTCCATCTTCTCTGTCTGCCTCTGTGGGCGACCGGGTG
 ACCATCACCTGCCGTGCCTCTCAGGATATCTCTAGGTATCTGGCCTGGTATCAGCAG
 20 AAGCCAGGTAAGGCGCCAAAGCTGCTGATCTACGCCGCCTCTTCTTTGCAGTCTGGT
 GTGCCATCTCGTTTCTCTGGTTCTGGTTCTGGCACCGACTTCACCCTGACCATCTCTT
 CTTTGCAGCCAGAAGACTTCGCCACCTACTACTGCGCGGCTTACGACTATTCTTTGG
 GCGGTTACGTGTTTCGGTGATGGTACCAAAGTGGAGATCAAA

AX1 FD CHAIN (FOR FABS) PROTEIN [SEQ ID NO: 17]

25 EVQLLES GGLVQPGGSLRLSCKASGFTFTSYMHWVRQAPGKGLEWIGRINPDSGSK
 YNEKFKGRATISRDN SKNTLYLQMNSLRAEDTAVYYCARGGRLSWDFDVWGQTLVT
 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPAVL
 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT

AX1 FD CHAIN (FOR FABS) NUCLEIC ACID [SEQ ID NO: 18]

30 gaagtgcagctgctggaatctggtggtgctggtgcagccaggtggtctctgcgtctgtcttgaaggcctctggttcacttcactcttac
 tacatgcactgggtgcgtcaggcaccaggttaagggctggaatggatcggtcggatcaaccagattctggtagtagtaagtacaacgagaa
 gttcaagggctgcccaccatctctagagacaactctaagaacacctgtactgcagatgaactctctgcgtgccgaggacactgcagtgta
 ctactgcgccctggtggtcgtttatcctgggactcgcagctctggggtcagggtagctggtgactgtctcgagcgcaagcaccacaaaggcc

catcgggtattccccctggcaccctcctccaagagcacctctgggggacagcggccctgggctgcctggcaaggactactccccgagcc
gggtgacgggtgctggaactcaggcgctctgaccagcggcgtgcacacctccccggctgtcctacagtcctcaggacttactccctcagca
gcgtgggtgactgtgccctccagcagctgggcaccagacctacatctgcaacgtgaatcacaagcccagcaacactaaggtggacaagaa
agttgagcccaaatctgtgacaaaactcacaca

5 **AX1-VH [SEQ ID NO: 19], CDRs underlined**

EVQLLESGGGLVQPGGSLRLSCKASGFTFTSYMHWVRQAPGKGLEWIGRINPDSGSTK
YNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARGGRLSWDFDVWGQGLVT
VSS

AX1-VH [SEQ ID NO: 20]

10 GAAGTGCAGCTGCTGGAATCTGGTGGTGGTCTGGTGCAGCCAGGTGGTTCTCTGCGT
CTGTCTTGCAAGGCCTCTGGTTTCACCTTCACTTCTTACTACATGCACTGGGTGCGTC
AGGCACCAGGTAAGGGTCTGGAATGGATCGGTCGGATCAACCCAGATTCTGGTAGT
ACTAAGTACAACGAGAAGTTCAAGGGTCGTGCCACCATCTCTAGAGACAACCTCTAA
GAACACCCTGTACTTGCAGATGAACTCTCTGCGTGCCGAGGACACTGCAGTGTACTA
15 CTGCGCCCGTGGTGGTCGTTTATCCTGGGACTTCGACGTCTGGGGTCAGGGTACGCT
GGTACTGTCTCGAGC

AX1 IGG2 HEAVY CHAIN PROTEIN [SEQ ID NO: 21]

EVQLLESGGGLVQPGGSLRLSCKASGFTFTSYMHWVRQAPGKGLEWIGRINPDSGSTK
YNEKFKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCARGGRLSWDFDVWGQGLVT
20 VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKS
25 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

AX1 IGG2 HEAVY CHAIN NUCLEIC ACID [SEQ ID NO: 22]

GAGGTCCAACTTTTGGAGTCTGGAGGAGGACTGGTCCAACCTGGAGGCTCCCTGAG
ACTGTCCTGTAAGGCATCTGGCTTCACCTTCACCTCCTACTATATGCACTGGGTGAG
ACAGGCTCCTGGCAAGGGATTGGAGTGGATTGGCAGGATAAACCCTGACTCTGGCA
30 GCACCAAATACAATGAGAAGTTCAAGGGCAGGGCTACCATCAGCAGGGACAACAGC
AAGAACACCCTCTACCTCAAATGAACTCCCTGAGGGCTGAGGACACAGCAGTCTA
CTACTGTGCCAGGGGAGGCAGACTGTCCTGGGACTTTGATGTGTGGGGACAAGGCA
CCCTGGTGACAGTGCCTCTGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCGC

CCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC
 TACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCTCTGACCAGCGGCGTG
 CACACCTTCCCGGTGTCTTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTG
 ACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTTAGATCACAA
 5 GCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCTGAGTGCC
 CACCGTGCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCTCTTCCCCCAAAC
 CCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGAC
 GTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGT
 GCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGG
 10 TCAGCGTCTCACCCTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC
 AAGGTCTCCAACAAAGGCCTCCAGCCCCATCGAGAAAACCATCTCCAAAACCAA
 AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGAGGAGATGA
 CCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCAGCGACATC
 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACACCTCC
 15 CATGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAG
 CAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAA
 CCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGGTAAA

AX1 FULL LIGHT CHAIN PROTEIN [SEQ ID NO: 23]

DIQMTQSPSSLSASVGDRTITCRASQDISRYLAWYQQKPGKAPKLLIYAASSLQSGVPS
 20 RFSGSGSGTDFTLTISSLQPEDFATYYCAAYDYSLGGYVFGDGTKVEIKRTVAAPSVFIFP
 PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSST
 LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

AX1 IGG LIGHT CHAIN PAIRED WITH IGG2 NUCLEIC ACID [SEQ ID NO: 24]

GACATCCAGATGACCCAGAGCCATCCTCCCTGTCTGCCTCTGTGGGAGACAGGGTG
 25 ACCATCACTTGTAGGGCAAGCCAGGACATCAGCAGATACCTGGCTTGGTATCAACA
 GAAGCCTGGCAAGGCTCCAAAACCTGCTGATTTATGCTGCCTCCTCCCTCCAATCTGG
 AGTGCCAAGCAGGTTCTCTGGCTCTGGCTCTGGCACAGACTTCACCCTGACCATCTC
 CTCCCTCCAACCTGAGGACTTTGCCACCTACTACTGTGCTGCCTATGACTACTCCCTG
 GGAGGCTATGTGTTTGGAGATGGCACCAAGGTGGAGATTAAGCGTACGGTGGCTGC
 30 ACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACCTGCCTCT
 GTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTG
 GATAACGCCCTCCAATCGGGTAACTCCAGGAGAGTGTACAGAGCAGGACAGCAA
 GGACAGCACCTACAGCCTCAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGAGA

AACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACA
AAGAGCTTCAACAGGGGAGAGTGT

Fab Protein Expression And Purification From TG1 Cells: 50 ml of overnight cultures for individual clones in 2YT/2% glucose/Carbenicillin 100 µg/ml were grown in 37 °C shaker incubator. In the second day, 750 mL to 1L of 2YT / 0.1% glucose /100ug/mL Carbenicillin was inoculated for each clone by transferring 5-10 ml of the overnight culture. The cultures were grown at 30 °C with shaking for approximately 3-4 hours until OD600 ~1. IPTG was added to the culture to reach the final concentration of 0.1-0.5 mM. After overnight IPTG induction at 22 °C, the cells pellets were collected by centrifugation at 10,000 rpm for 10-15 minutes, to proceed for periplasmic preparation.

Soluble Fabs were extracted from cell periplasm. The periplasmic preparation was performed as follows. The TG1 pellet was re-suspended in 20mL pre-chilled PPB buffer (20% Sucrose + 2mM EDTA + 30mM Tris, pH = 8), and incubated on ice for 1 hour. The supernatant with soluble Fab was collected by centrifugation. Subsequently, the cell pellet was further re-suspended in 20mL pre-chilled 5mM magnesium sulfate with 1 hour incubation on ice. Two supernatants were combined for further Fab purification.

The soluble Fab from the periplasmic extraction was purified using a HiTrap Protein G HP column (GE Healthcare). The column was initially equilibrated with equilibration buffer (PBS or Tris, pH 7.3). The supernatant from periplasmic preparation was loaded onto a 1-ml or 5-mL protein-G column (HiTrap, GE healthcare). After wash with 10 column volumes (CVs) of equilibration buffer, Fab protein was eluted with 8 CVs of elution buffer (0.3 M acetic acid, pH3). The eluted fractions were collected, and neutralized with 0.5 volume of 1M Tris, pH 9 buffer. The Fab samples were buffer-exchanged into PBS using Amicon centrifugal filters with 10 kD molecular weight cutoff. The quality of purified Fab was analyzed using size exclusion HPLC (SE-HPLC). Purified Fab was also used for ELISA assay and Biacore assay (below). Overall, the summary of Fab yields is ~1 – 2 mg/L with high degree of variability, from less than 1 mg/L to well over 10 mg/L. All Fabs show single main peak by SE-HPLC. The ELISA assay results confirmed all Fab bound to human PCSK9 antigen.

Anti-PCSK9 Monoclonal Antibody Purification From Glycoengineered *Pichia* *Pastoris*: Anti-PCSK9 monoclonal antibody expressed in glyco-engineered *Pichia pastoris* GFI 5.0 host YGLY8316, which is capable of transferring terminal galactose at its complex N-linked glycan. Anti-PCSK9 heavy and light chains were codon optimized and expressed under methanol tightly inducible promoter AOX1 using *Saccharomyces cerevisiae* alpha mating factor

presequence as secretion signal sequence. The glycoengineered *Pichia* strain producing this antibody was named as YGLY18513. Anti-PCSK9 antibody from YGLY18513 was captured from cell free supernatant media by affinity chromatography using MabSelect™ medium from GE Healthcare (Cat. # 17-5199-01). The cell free supernatant was loaded on to Mabselect
5 column (XK 16/20, 1.6cm x 10.0 cm) pre-equilibrated with three column volume of 20mM Tris-HCl pH7.0 at a flow rate of 5.0mL/min. The column was washed with three column volumes of the 20mM Tris-HCl pH7.0 followed by a five column volume wash with 20mM Tris-HCl pH7.0 containing 1M NaCl to remove the host cell proteins. The anti-PCSK9 antibody was eluted with
10 five column volume of 100mM Glycine, 100mM Arginine pH 3.0 and immediately neutralized with 1M Tris-HCl pH8.0. Antibody was well expressed in *Pichia*.

Strong Cation Exchange Chromatography employing Source 30S resin from GE Healthcare (Cat # 17-1273-02) was used as the second step purification to remove the clipped species and aggregates. Mabselect pool of the anti-PCSK9 antibody was 5X diluted with 25mM Sodium acetate pH5.0 and loaded on to the Source 30S column pre-equilibrated with three
15 column volume of 25mM Sodium acetate pH5.0. After loading, the column was washed with three column volume of the 25mM Sodium acetate pH5.0 and elution was performed by developing a linear gradient over ten column volume ranging from 100mM to 150mM Sodium chloride in 25mM Sodium acetate pH5.0. The fractions containing good assembled anti-PCSK9 antibody was pooled together. The Source30S pooled fractions that contained the anti-PCSK9
20 antibody was buffer exchanged into the formulation buffer containing 6% Sucrose, 100mM Arginine, 100mM Histidine pH6.0 (HyClone® Cat # RR10804.02) and sterile filtered using 0.2µm PES (PolyEtherSulfone) membrane filter and stored @4°C until release.

EXAMPLE 2

25 Measurement of PCSK9 in Human EDTA Plasma

The assay employs a Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFLIA) Time-Resolved Fluorometry (TRF) method. DELFLIA TRF assays rely on the fluorescent properties of lanthanide chelate labels which allow for long fluorescence decay times and large Stokes' shifts; see Figures 1A-B. The long fluorescence decay times allow the
30 user to measure fluorescence after background fluorescence has subsided, effectively reducing background emissions that normally accompany samples. In addition, the assay has a large Stokes shift (360nm excitation/620nm emission) which allow for clean peak fluorescence detection without interfering peaks and peak shoulders. These characteristics of DELFLIA TRF

effectively reduce background emission to a level that allows for increased measurement sensitivities.

The assay relies on the direct adsorption of a capture antibody onto the surface of a high binding Costar Plate. Samples, standards, and controls are added to the well followed by secondary antibody and after immunoreactions; the lanthanide label is dissociated from the complex in enhancement solution. The free lanthanide (Eu^{3+} , Europium) rapidly forms a new highly fluorescent and stable chelate with the components of the enhancement solution. For analysis, plates are loaded into the Biotek Synergy 2 instrument and excited at a wavelength of 360nm and the emission is read at 620nm. The assay quantitatively measures the concentration of PCSK9 in human plasma.

Equipment: Biotek Synergy 2 Plate Reader (Excitation filter-360±40nm, Emission filter-620±40nm); Assorted pipettors; Vortex Mixer; Plate Shaker; Biohit Multichannel Pipettor (1200µL); Beckman Coulter Biomek FX; Boekel Jitterbug Model 130000

Supplies: Microplate Adhesive Film (USA Scientific cat# 2920-0000); 1.5 mL microfuge tubes (Eppendorf, Cat # 022363204); Black High Binding Assay Plate (Costar #3295); Pipet tips; EDTA Vacutainer Tubes for Plasma Collection (BD, cat# 366643)

Reagents: (1) DELFIA Components (Perkin Elmer) [Streptavidin/Europium (100µg /mL), stored at 4 °C (catalog# 1244-360); DELFIA Assay Buffer, stored at 4 °C (catalog# 1244-111); DELFIA Enhance, stored at 4 °C (catalog# 1244-105)]; (2) Antibodies [AX213 (monoclonal Ab to human PCSK9) capture antibody, stored at 4 °C and AX1 (monoclonal Ab to human PCSK9) biotinylated secondary antibody, stored at 4 °C]; (3) Heterophilic Blocking Reagent 1 (HBR1, Purified), Scantibodies Laboratory, catalog# 3KC533 ~ 20 mg/mL; (4) 10% Tween-20 stored at room temperature (Bio-Rad, catalog# 161-0781); (5) MSD Blocker A: stored at 4 °C (Meso Scale Discovery, catalog# R93AA-1); (6) TBS-T Wash Buffer (Sigma catalog #T-9039) [1 packet mixed into 1 liter Milli-Q grade water, Final concentration: 50 mM Tris-buffered saline, 0.05% Tween-20 in 1000 mL, stored at room temperature]; (7) 1X Phosphate Buffered Saline Solution (Fluka, catalog# 79383) [5.0 mL 10X PBS was diluted into 45 mL Milli-Q grade water, Final concentration: 1X]; (8) Coating Solution [prepared immediately before use as follows: 5.00 µL of AX213 (stock =10.05 mg/mL) into 5995 µL of 1X PBS, Coat Solution is 8.375 µg/mL AX213]; (9) Blocking Solution [prepared day of experiment as follows: 900 mg of MSD Blocker A (BSA) into 30.0 mL of TBS-T Wash Buffer, Final Concentration: 3%]; (10) Assay Buffer (AB) [prepared day of experiment as follows in Table 1 below]:

TABLE 1

<u>Component</u>	<u>Volume</u>	<u>Final Concentration</u>
Blocking Solution	5000 μ L	1% BSA
TBS-T Wash Buffer	9490 μ L	- -
10% Tween-20	375 μ L	0.25%
HBR(18.44 mg/mL)	138.8 μ L	30 μ g HBR to 25 μ L plasma
<u>Total volume</u>	<u>15000 μL</u>	

(11) 1% BSA [prepared day of experiment as follows: 4.0 mL Blocking Solution was pipetted into 8.0 mL TBS-T Wash Buffer]; (12) Biotinylated Secondary Antibody Solution [prepared immediately before use as follows: 5.5 μ L AX1 Ab (stock =1.0 mg/mL) into 5494.5 μ L 1% BSA, Final concentration: 1.0 μ g/ML]; and (12) Strep-Eu Solution [prepared immediately before use and protected from light, 8.0 μ L Strep-Eu (stock = 100 μ g /mL) into 7992 μ L DELFIA Assay Buffer, Final concentration: 0.100 μ g/mL].

Preparation of Calibrator Curve: The master stock concentration of PCSK9 is 1.32 mg/mL. A 30 μ g/mL stock was prepared using a 1:44 dilution with Assay Buffer from the master stock.

TABLE 2

Calibrator (Nm)	Volume Calibrator / Stock	Volume Assay Buffer	Dilution Factor
10.25	6.0 μ L of 30 μ g/mL Stock (384.4 nM)	219.0 μ L	37.5
3.42	75 μ L of 10.25 nM Calibrator	150 μ L	3.0
1.14	75 μ L of 3.42 nM Calibrator	150 μ L	3.0
0.38	75 μ L of 1.14 nM Calibrator	150 μ L	3.0
0.13	75 μ L of 0.38 nM Calibrator	150 μ L	3.0
0.04	75 μ L of 0.13 nM Calibrator	150 μ L	3.0
0.014	75 μ L of 0.04 nM Calibrator	150 μ L	3.0
0.004	75 μ L of 0.014 nM Calibrator	150 μ L	3.0

Biomek FX Procedure: All calibrations of the Span -8 Head were specifically created for PCSK9. All robot pipetting functions were performed using the Span-8

Head. The program is divided into three sections: (1) Sample Dilution: 140 μL of assay buffer was added to each well in a polypropylene dilution plate; 20 μL of each QC and clinical sample were added to the wells containing the assay buffer; (2) Sample Addition: Each QC and clinical sample in the dilution plate was mixed 3 times; 50 μL of each QC and clinical sample were added in duplicate to the Costar Assay Plate; and Standard Addition: 50 μL of each calibrator was added in duplicate to the Costar Assay Plate.

Biotek Synergy 2 Settings: Plate was shaken for 5 minutes on the lowest setting and then read. Excitation and Emission, 360 nm (40nm range) and 620 nm (40nm range), respectively. Delay Time is 250 μSec with a total count time of 1000 μSec .

Assay Procedure: (1) Plate Coating: 60 μL of Coating Solution was added per well, left at 4°C overnight, and sealed with a plated sealer. (2) Blocking the Plate: Without washing the plate, 150 μL of Blocking Solution was added per well and incubated shaking for 1 hour at room temp. Jitterbug was turned on and temp. set to 37°C. (3) Recombinant PCSK9 Curve: 6.0 μL of the 30 $\mu\text{g}/\text{mL}$ stock was added into 219.0 μL Assay Buffer, and 3-fold serial diluted using 75 μL calibrator into 150 μL Assay Buffer. (4) Sample and Calibrator Addition: After Blocking, plate was washed as described in step 1, and run on Biomek FX. The program diluted the samples and QCs 1:8 in Assay Buffer. Calibrators (standards) were not diluted. Final volume per well was 50 μL . Plate was then incubated in the Jitterbug for 1 hour shaking at 37°C. (5) Detection Antibody: 50 μL of the biotinylated secondary antibody solution was added to each well. Final Concentration of Antibody was 1.0 $\mu\text{g}/\text{mL}$. Plate was incubated 1 hour shaking at room temp. (6) Strep-Eu: 75 μL of the Strep-Eu solution was added to each well. Concentration of Strep-Ru was 0.10 $\mu\text{g}/\text{mL}$. Plate was incubated 20 min shaking at room temp. (7) Enhance Solution: 100 μL of DELFIA Enhance solution was added to each well, and the plate covered with black lid and read on Biotek Synergy 2 Plate Reader. (8) Read plate: The DELFIA Program was run. Plate was shaken 5 minutes, then was read at an excitation of 360nm and emission of 620nm.

Calculations: All calculations were completed using the Gen5 Software. Concentrations of unknowns were derived from the calibrator curve in nM PCSK9.

Results: Figure 2 illustrates the recombinant human PCSK9 standard curve diluted in assay buffer. The range of the curve is 10.26 nM to 0.005 nM. Figure 3 illustrates the biological variability of six normal healthy volunteers shown on three different days over three weeks. Concentration shown in nM.

WHAT IS CLAIMED IS:

1. A method of measuring circulating PCSK9 levels in a biological sample comprising the steps of performing an immunoassay on a biological sample obtained from a subject and comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9, wherein a coating or capture antibody is AX213 and a detecting antibody is AX1.
5
2. The method of claim 1 wherein AX213 and AX1 are full length antibodies.
3. The method of claim 1 wherein AX213 comprises a variable light ("VL") sequence comprising SEQ ID NO: 3 and a variable heavy ("VH") sequence comprising SEQ ID NO: 7, and AX1 comprises a variable light ("VL") sequence comprising SEQ ID NO: 15 and a variable heavy ("VH") sequence comprising SEQ ID NO: 19.
10
4. The method of claim 1 wherein AX213 comprises a light chain comprising SEQ ID NO: 1 or SEQ ID NO: 11 and a heavy chain comprising SEQ ID NO: 9 and AX1 comprises (a) light chain comprising SEQ ID NO: 13 or SEQ ID NO :23 and (b) a heavy chain comprising SEQ ID NO: 21.
15
5. The method of claim 1 wherein performing an immunoassay comprises: (a) depositing a biological sample on a support having immobilized anti-PCSK9 antibody AX213; (b) contacting the support having the biological sample deposited thereon with anti-PCSK9 antibody AX1 bearing a detectable label; and (c) detecting the label.
20
6. The method of claim 1, wherein the immunoassay is a solid phase immunoassay.
25
7. The method of claim 6, wherein the solid phase immunoassay is a dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA).
8. The method of claim 1, wherein said sample is selected from the group consisting of blood, plasma and serum.
30

9. The method of claim 8 wherein the blood, plasma or serum is from a human.

10. A method for performing an immunoassay on a biological sample which has been contacted with a putative PCSK9 antagonist which comprises (a) depositing the biological sample on a support having immobilized anti-PCSK9 antibody AX213; (b) contacting the support having the biological sample deposited thereon with anti-PCSK9 antibody AX1 bearing a detectable label; (c) detecting the label; and (d) comparing the level of PCSK9 in said sample against a standard having a known concentration of PCSK9.

11. The method of claim 10 wherein AX213 and AX1 are full length antibodies.

12. The method of claim 10 wherein AX213 comprises a variable light ("VL") sequence comprising SEQ ID NO: 3 and a variable heavy ("VH") sequence comprising SEQ ID NO: 7, and AX1 comprises a variable light ("VL") sequence comprising SEQ ID NO: 15 and a variable heavy ("VH") sequence comprising SEQ ID NO: 19.

13. The method of claim 10 wherein AX213 comprises a light chain comprising SEQ ID NO: 1 or SEQ ID NO: 11 and a heavy chain comprising SEQ ID NO: 9 and AX1 comprises (a) light chain comprising SEQ ID NO: 13 or SEQ ID NO: 23 and (b) a heavy chain comprising SEQ ID NO: 21.

14. The method of claim 10, wherein the immunoassay is a solid phase immunoassay.

15. The method of claim 14, wherein the solid phase immunoassay is a dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA).

16. The method of claim 10, wherein said sample is selected from the group consisting of blood, plasma and serum.

17. The method of claim 16 wherein the blood, plasma or serum is from a human.

18. A kit for measuring circulating PCSK9 levels in a biological sample, comprising:

a). a biological sample collection device;

b). a composition comprising an immunoassay which comprises a coating or capture antibody and a detection antibody; and

c). a means for detecting a reaction between PCSK9 antigen in the sample and antibodies in the immunoassay;

wherein the coating or capture antibody is AX213 and the detecting antibody is AX1.

10

19. The kit of claim 18 wherein AX213 and AX1 are full length antibodies.

20. The method of claim 19 wherein AX213 comprises a variable light ("VL") sequence comprising SEQ ID NO: 3 and a variable heavy ("VH") sequence comprising SEQ ID NO: 7, and AX1 comprises a variable light ("VL") sequence comprising SEQ ID NO: 15 and a variable heavy ("VH") sequence comprising SEQ ID NO: 19.

21. The method of claim 20 wherein AX213 comprises a light chain comprising SEQ ID NO: 1 or SEQ ID NO: 11 and a heavy chain comprising SEQ ID NO: 9 and AX1 comprises (a) light chain comprising SEQ ID NO: 13 or SEQ ID NO: 23 and (b) a heavy chain comprising SEQ ID NO: 21.

20

1/3

Excitation 1 at 340 nm

1000 cycles/s




FIG.1A




FIG.1B

2/3




FIG.2

3/3

	PCSK9 (nM)					
	E	F	G	H	I	J
Week 1	1.63	5.52	3.27	5.40	5.16	4.57
Week 3	3.21	4.98	4.04	3.92	3.49	4.23
Week 4	1.55	3.86	4.44	4.05	5.07	4.54
%CV	43.83	17.74	15.15	18.40	20.57	4.17

FIG.3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/54595

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/53 (2010.01)

USPC - 435/7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC: 435/7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 435/7.1; 435/7.2; 435/7.94; 435/968 (text search)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Electronic data bases: PubWEST (PGPB, USPT, EPAB, JPAB); Google Scholar; GenCore Sequence Search (AA)

Search terms: Proprotein convertase subtilisin/kexin type 9 (PCSK9, NARC1, NARC-1, PC9); monoclonal, antibody, AX213, AX1, immunoassay, solid phase immunoassay, ELISA, dissociation-enhanced lanthanide fluorescence immunoassay (DELFLIA)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LAMBERT et al. Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clin Chem June 2008 Vol 54 No 6 Pages 1038-1045. Especially pg 1039 right col para 4, pg 1039 left col para 4, pg 1040 right col para 4, pg 1040 fig 1.	1-21
A	US 2006/0177896 A1 (MACH et al.). 10 August 2006 (10.08.2006). Especially SEQ ID NO: 4	1-21
A	US/ 2006/ 0015952 A1 (FILVAROFF et al.). 19 January 2006 (19.01.2006). Especially SEQ ID	1-21
A	US 2004/0236078 A1 (CARTER et al.) 25 November 2004 (25.11.2004). Especially SEQ ID NO: 3.	1-21
A	US 2003/0021790 A1 (HSEI et al). 30 January 2003 (30.01.2003). Especially SEQ ID NO: 52.	1-21
A	STRIDSBERG et al. A Two-site Delfia Immunoassay for Measurements of the N-terminal Peptide of pro-Atrial Natriuretic Peptide (nANP). Upsala J Med Sci 1997 Vol 102 No 2 Pages 99-108. Especially abstract. (teaches DELFLIA Immunoassay).	7,15

 Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 2010 (16.12.2010)

Date of mailing of the international search report

13 JAN 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/54595

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/057459 A2 (SPARROW et al.) 15 May 2008 (15.05.2008). Especially pg 22 ln 2-10 (teaches anti-PCSK9 monoclonal antibodies).	1-21
A	WO 2008/125623 A2 (MIKHAILOV et al.) 23 October 2008 (23.10.2008). Especially pg 7 ln 12-27 (teaches anti-PCSK9 monoclonal antibodies).	1-21
A	US 2009/0232795 A1 (CONDRA et al.) 17 September 2009 (17.09.2009). Especially para [0058] (teaches anti-PCSK9 monoclonal antibodies).	1-21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/54595

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

on paper

in electronic form

b. (time)

in the international application as filed

together with the international application in electronic form

subsequently to this Authority for the purposes of search

2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.3 SEQ ID NOs: 1,3,7,9,13,15,19,21,23

专利名称(译)	PCSK9免疫测定		
公开(公告)号	EP2494355A4	公开(公告)日	2013-05-01
申请号	EP2010827502	申请日	2010-10-29
[标]申请(专利权)人(译)	默沙东CORP.		
申请(专利权)人(译)	默沙东CORP.		
当前申请(专利权)人(译)	默沙东CORP.		
[标]发明人	ICHETOVKIN MARINA CHEN ZHU LEGRAND CHERYL		
发明人	ICHETOVKIN, MARINA CHEN, ZHU LEGRAND, CHERYL		
IPC分类号	G01N33/53 G01N33/573		
CPC分类号	G01N33/573 G01N2333/96425		
优先权	61/368081 2010-07-27 US 61/256752 2009-10-30 US		
其他公开文献	EP2494355A1		
外部链接	Espacenet		

摘要(译)

使用PCSK9拮抗剂的方法。更具体地，通过免疫测定法测量生物样品中的循环PCSK9水平的方法。